Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PTCT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPTC Therapeutics stockholders approve routine annual meeting matters
Filed June 5, 2026 · Period ending June 2, 2026 · ~1 min read
Key Changes
-
low
Four Class I directors elected to three-year terms through 2029: Jessica Chutter, Matthew B. Klein, Stephanie S. Okey, and Jerome B. Zeldis, all receiving majority support.
Item 5.07 verify on EDGAR → -
low
Ernst & Young LLP ratified as independent auditor for fiscal 2026 with 99.5% approval, maintaining continuity in external audit relationship.
Item 5.07 verify on EDGAR → -
low
Executive compensation approved in non-binding say-on-pay vote with 97.9% support, indicating strong stockholder backing of management pay practices.
Item 5.07 verify on EDGAR →
Summary
PTC Therapeutics held its 2026 Annual Meeting on June 2, with stockholders voting on standard governance matters. All proposals passed with strong support, including the election of four directors to three-year terms, ratification of the company's auditor, and approval of executive compensation. The high approval rates across all items suggest stockholder satisfaction with current board composition and management practices.
For retail investors, this filing represents routine corporate housekeeping with no material business developments. The strong vote tallies indicate no significant governance concerns or stockholder dissent. Investors should continue monitoring the company's quarterly earnings reports and pipeline updates for material information affecting the business and stock value.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
PTC Therapeutics held its 2026 Annual Meeting, electing four Class I directors, ratifying Ernst & Young as auditor, and approving executive compensation.
Show 3 minor / wording changes
Added in current filing · verify on EDGAR →
The stockholders of the Company elected four Class I directors, each to hold office until the Company’s 2029 annual meeting of stockholders or until his or her successor has been duly elected and qualified
Four Class I directors were elected at the June 2, 2026 Annual Meeting: Jessica Chutter, Matthew B. Klein, Stephanie S. Okey, and Jerome B. Zeldis. All four received majority support with votes ranging from approximately 68.9 million to 71.9 million in favor. These directors will serve three-year terms until the 2029 annual meeting.
Added in current filing · verify on EDGAR →
The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by the Company’s stockholders with 76,170,292 votes “For,” 355,794 votes “Against,” and 15,520 votes “Abstained.”
Stockholders ratified Ernst & Young LLP as the independent auditor for fiscal year 2026 with overwhelming support (approximately 99.5% of votes cast in favor). This is a routine annual vote confirming continuity in the company's external audit relationship.
Added in current filing · verify on EDGAR →
The non-binding advisory proposal on named executive officer compensation was approved by the Company’s stockholders with 71,166,204 votes “For,” 1,492,801 votes “Against,” 24,290 votes “Abstained,” and 3,858,311 broker non-votes.
The say-on-pay proposal received approximately 97.9% support from votes cast (excluding broker non-votes), indicating strong stockholder approval of the company's executive compensation practices. This is a non-binding advisory vote required under SEC rules.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify